The nephrotoxicity of immune checkpoint inhibitor-based combinations
A partir d'une revue de la littérature, cette étude analyse la néphrotoxicité des inhibiteurs de points de contrôle immunitaire utilisés en combinaison chez les patients atteints d'un cancer
Immune checkpoint inhibitors (ICIs) have unveiled a new era in the treatment of cancer with unprecedented survival data in multiple tumours [1]. However, there remain a number of patients with only mediocre responses to ICIs, which prompted the investigation of ICI-based combinations to circumvent treatment resistance [2]. Recent studies have shown that ICI-based combinations caused an increased risk of adverse events namely renal adverse events (rAEs) [3,4], which seem overall to be rare compared with the more common liver, gastrointestinal, skin and pulmonary toxicities [5].